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Abstract
Background: Diet is a major contributor to metabolic disease risk, but there is controversy as to whether increased
incidences of diseases such as non-alcoholic fatty liver disease arise from consumption of saturated fats or free
sugars. Here, we investigate whether a sub-set of triacylglycerols (TAGs) were associated with hepatic steatosis and
whether they arise from de novo lipogenesis (DNL) from the consumption of carbohydrates.
Results: We conduct direct infusion mass spectrometry of lipids in plasma to study the association between
specific TAGs and hepatic steatosis assessed by ultrasound and fatty liver index in volunteers from the UK-based
Fenland Study and evaluate clustering of TAGs in the National Survey of Health and Development
UK cohort. We find that TAGs containing saturated and monounsaturated fatty acids with 16–18 carbons are
specifically associated with hepatic steatosis. These TAGs are additionally associated with higher consumption of
carbohydrate and saturated fat, hepatic steatosis, and variations in the gene for protein phosphatase 1, regulatory
subunit 3b (PPP1R3B), which in part regulates glycogen synthesis. DNL is measured in hyperphagic ob/ob mice,
mice on a western diet (high in fat and free sugar) and in healthy humans using stable isotope techniques
following high carbohydrate meals, demonstrating the rate of DNL correlates with increased synthesis of this
cluster of TAGs. Furthermore, these TAGs are increased in plasma from patients with biopsy-confirmed steatosis.
Conclusion: A subset of TAGs is associated with hepatic steatosis, even when correcting for common confounding
factors. We suggest that hepatic steatosis risk in western populations is in part driven by increased DNL following
carbohydrate rich meals in addition to the consumption of saturated fat.
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Background
Hypertriglyceridemia is a substantial co-morbidity associ-
ated with non-alcoholic fatty liver disease (NAFLD), cardio-
vascular disease (CVD), type 2 diabetes mellitus (T2DM),
hypertension and cancer [1–4]. Triacylglycerols (also called
triglycerides [TAGs]) are the largest energy store in the
body and are transported from their major stores in adipose
tissue to sites with a high metabolic demand, in particular
slow-twitch skeletal muscle, heart and liver [5]. Diet has a
major impact on TAG composition, total fatty acid intake
[6, 7] and the synthesis of new fatty acids (FAs) in the liver
by de novo lipogenesis (DNL) [8]. In the clinic, blood
plasma TAG concentrations are measured by biochemical
assay, but such assays do not discriminate between different
TAG species that contribute to the total, limiting diagnostic
and mechanistic interpretation.
Liquid chromatography mass spectrometry (LC-MS)
separates TAG species by hydrophobicity and molecular
mass [9]. Using such an approach, Rhee et al. reported
positive associations between plasma TAG(44:1),
TAG(46:1), TAG(48:1) and TAG(48:0) and the relative
risk of developing T2DM in the Framingham Heart
Study independent of age and sex [10]. Similarly, in the
Bruneck cohort (Austria), TAG(54:2) was associated with
increased risk of CVD [11]. Specific TAGs have also
been associated with both pre-diabetes and T2DM, and
have been shown to improve predictions of T2DM when
used alongside classic risk factors such as HbA1c and
total TAGs [12, 13]. Kotronen et al. examining TAG spe-
cies in individuals across a broad ranges of insulin sensi-
tivity hypothesised that circulating concentrations of
specific TAGs (TAG(16:0/16:0/18:1) and TAG(16:0/18:1/
18:0)) may be better predictors of the homeostatic model
assessment of insulin resistance (HOMA-IR) than total
TAG blood content [14], while TAGs containing unsat-
urated essential FAs were negatively associated with IR.
Across these studies, the TAG species have in common
relative enrichments for palmitate, stearate and oleate
fatty acids, and studies using gas chromatography
(GC)-MS have also reported associations between these
FAs from total lipid extracts and increased risk of devel-
oping T2DM [15].
Although hepatic DNL is traditionally believed to
contribute minimally to the total lipid pool in humans, in-
creased rates of DNL have been described in both NAFLD
and rare forms of IR and metabolic disease [16]. Semple et
al. used deuterium labelled water to directly investigate
DNL in those with either insulin signalling defects or lipo-
dystrophy, describing increased rates of DNL with IR [17].
In addition, the plasma content of palmitoleic acid (C16:1
n-7) has been shown to be a sensitive marker for NAFLD
[18]. Using direct infusion (DI)-MS, we demonstrated that
individuals with lipodystrophy have increased TAGs se-
lectively enriched for palmitate, stearate and oleate and
these TAGs are predominantly found in VLDL [19]. In
lipodystrophy, where adipose tissue depots are either to-
tally or partially lacking, post-prandial glucose is metabo-
lised in the liver, increasing hepatic DNL when glycogen
reserves are replete. Furthermore, these patients have se-
vere, peripheral IR and hyperinsulinemia, further increas-
ing hepatic DNL when glucose is in excess. Here, we have
conducted an observational epidemiological analysis, two
murine studies, and a human feeding experiment to char-
acterise the determinants of TAG species, and in particu-
lar how these TAGs are related to DNL and hepatic fat.
Results
In this manuscript, we have conducted three inter-related
studies: an observational study with two cohorts (Fenland
and National Survey of Health and Development [NSHD]
cohorts), two murine experiments involving genetic and
dietary-induced hepatic steatosis, and a carbohydra
te-overfeeding trial in humans. We designed the cohort
analyses to identify key TAG species associated with hep-
atic fat in healthy adults; two murine experiments to de-
termine whether the specific TAG species correlated with
hepatic DNL and a ‘western diet’ (WD) high in both satu-
rated fat and free sugar; and a human feeding intervention
to test whether dietary carbohydrates influence the spe-
cific TAGs. In addition, in the cohort analysis, we exam-
ined whether the specific TAG species were associated
with selected dietary, genetic and lifestyle factors. Finally,
we confirmed our TAG biomarkers for fatty liver in sam-
ples from patients with biopsy confirmed liver steatosis.
DI-MS of 1507 samples of the subset of the Fenland co-
hort detected 170 formula-assigned lipids common across
the dataset, with the detection of lyso-phosphatidylcholines,
diacylglycerols, phosphatidylcholines, phosphatidyletha-
nolamines, sphingomyelins and TAGs (Fig. 1a). Before
normalisation, the mean coefficient of variation (CV) for
individual lipid species in the 100% QC pool sample
across the study was 17%, with the QC samples clustering
at the centre of the sub-cohort of Fenland when examined
using principal component analysis (PCA) (Fig. 1b).
Applying a simple normalisation whereby the total inten-
sities of samples were corrected by normalising the quality
control (QC) samples reduced the mean CV for all indi-
vidual lipid species to 11%, further improving clustering of
QC samples (Fig. 1c).
Next, to investigate clustering within the dataset, clus-
tering tendency was tested using the Hopkin’s statistic
[20] which indicated that the data points for individual
lipids were non-uniformly distributed (H = 0.76, p < 0.05,
where H→ 1 indicates highly clustered, H = 0.5 ran-
domly distributed and H = 0 uniformly distributed). Both
hierarchical clustering and PCA indicated that TAGs
and DAGs formed a distinct cluster from the other lipid
species (Additional file 1: Figure S1a and S1b, Table S1).
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However, it should be noted that the Hopkin’s statistic is
sensitive to the number of species in a given group and so
may have missed clustering in the other lipid classes
which have smaller numbers of lipid species associated
with them. Next, the substructure of the non-glycerolipid
species were investigated using PCA. This indicated that
while phosphatidylcholines were relatively disperse, other
species clustered according to lipid class (Additional file 1,
Figure S1c and S1d), with similar results produced for
K-means and self-organising maps (SOM) clustering
(Additional file 1, Figure S1e and S1f). Hopkin’s statistics
of each lipid class determined that only TAGs had statisti-
cally significant clustering tendency (Fig. 1d).
DI-MS reveals discrete clusters of TAGs in human blood
plasma
The TAG profiles were analysed by Bayesian Hierarch-
ical clustering, producing three distinct clusters (Fig. 2a).
This included a large cluster of TAGs containing shorter,
more saturated FAs (cluster 3), as well as two large clus-
ters containing more unsaturated FAs (clusters 1 and 2)
(Fig. 2b). Using the integral values for each m/z for these
TAG species it was possible to compare the relative
intensities of these clusters, with cluster 3 representing
~ 30% of the TAG total intensities for the mass spectra.
Replication of TAG profile in the NSHD cohort
To examine whether this clustering is present in other
populations we examined the NSHD study, another UK
cohort, and profiled the lipids within blood plasma from
1701 individuals. Again, Hopkin’s statistic indicated that
sub-clustering was only present in the TAG species
(Additional File 1, Figure S2). Focussing on the TAG
species, again Bayesian hierarchical clustering produced
distinct clusters of TAG species (Fig. 2c). Clusters 1 and
4 were dominated by TAGs containing very short, unsat-
urated FAs (cluster 1 ~ 12%) and short saturated/mono-
unsaturated FAs (cluster 4 ~ 14%), respectively. Cluster
2 consisted of TAGs (~ 46%) containing longer, polyun-
saturated FAs (~ 46%) similar in composition to those in
cluster 2 of the Fenland cohort. Cluster 3 contained the
TAGs found in cluster 3 of the Fenland cohort, contain-
ing saturated and monounsaturated FAs with ~ 16–18
carbons in length. There was also a similar distribution
of TAGs compared to Fenland (Fig. 2d), although NSHD
had a greater proportion of TAGs only containing
saturated FAs. While more TAGs were detected in
samples from NSHD, limiting comparisons to the 25
common TAGs between the two studies, overall there
was similarity between the clusters identified in both co-
horts (Additional File 1, Figure S3).
TAG profile of adults with hepatic steatosis determined
by the fatty liver index (Fenland)
Fatty liver index (FLI) is a surrogate marker of fatty liver
determined by ultrasound, composed of BMI, waist cir-
cumference, TAGs and gamma-glutamyl transferase
(GGT) concentration [21, 22]. By this measure, steatosis
Fig. 1 High-resolution direct infusion mass spectrometry (DI-MS) of blood plasma from the Fenland cohort. a High-resolution mass spectrum
from a typical blood plasma sample analysed by DI-MS. chol cholesterol, lyso-PC lysophophatidylcholines, DAG diacylglycerols, CE cholesterol
esters, PC phosphatidylcholines, SM sphingomyelins, TAG triacylglycerols b Principal component analysis (PCA) of samples from the Fenland
cohort (green circles) and pooled quality control samples (red circles) before normalisation. c As (b) but following batch correction normalising the
total intensity of QC samples across the 19 96-well-plates used to analyse the samples from Fenland. d Hopkin’s statistic of individual lipid classes
reveals that only TAGs have significant substructure in the Fenland dataset. The critical value is displayed as a dashed red line. CE cholesterol
esters. PE phosphatidylethanolamines, LPC lysophosphatidylcholines, SM sphingolipids, PC phosphatidylcholines, TG triacylglcerols
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was indicated in 493 participants (33%, FLI ≥ 60). A ro-
bust model could be built using orthogonal partial least
squares discriminant analysis (OPLS-DA) to separate
those with and without fatty liver disease according to
the FLI score (the amount of variance in the data repre-
sented by the model (R2(X)) = 62%, R2(Y) = 46%,
goodness of fit of the model (Q2) = 42%; Fig. 3a). The
OPLS-DA model passed the random permutation test
(Fig. 3b) and cross-validation analysis of variance
(CV-ANOVA) (p < 1*10−30). This was driven by relative
increases in TAGs and DAGs in the blood plasma of
those with fatty liver disease, particularly those
Fig. 2 Examining the distribution of triacylglycerols (TAGs) in Fenland and National Survey of Health and Development (NSHD) cohorts. a Bayesian
Hierarchical Cluster Analysis (B-HCA) of the TAG distributions as measured by DI-MS in the Fenland cohort. Relative intensities are shown of the major
three clusters. TAGs are identified by total number of carbons in the fatty acid side chains: total number of double bonds in the fatty acid side chains.
b Pie chart of the relative distribution of different TAGs in the Fenland cohort. c B-HCA of the TAG distributions as measured by DI-MS in the NSHD
cohort. Relative intensities are shown of the major 3/4 clusters. d Pie chart of the relative distribution of different TAGs in the NSHD cohort
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containing saturated and monounsaturated FAs ~ 16–18
carbons in length, alongside a relative decrease in phos-
phatidylcholines and cholesterol esters (Fig. 3c).
TAG profile of adults with hepatic steatosis determined
by ultrasound (Fenland)
As FLI is in part determined by serum TAG concentra-
tions, it is possible that the association between FLI and
the blood lipidome was driven by total TAG concentra-
tion and not hepatic steatosis, per se. To examine the
association between the presence of hepatic steatosis
and the plasma lipidome further, we examined the sub-
set of 896 individuals who had been characterised by
ultrasound and had good quality mass spectra in the
sub-cohort of Fenland. This group consisted of 26% with
mild-moderate steatosis (scores 5–10) and 74% with no
steatosis (scores 3–4) (Table 1). OPLS-DA readily sepa-
rated the two groups (R2(X) = 62%, R2Y = 22%, Q2 = 17%;
Fig. 3d), and the model passed cross-validation by
random permutation (Fig. 3e) and by CV-ANOVA
Fig. 3 a Orthogonal partial least squares discriminant analysis (OPLS-DA) of individuals with (blue) and without (green) hepatic steatosis as assessed by
fatty liver index. b Permutation validation of the plot in (a). R2 and Q2 values to the left of the plot are from random models compared with the values
for the true model on the right. c S-plot of discriminatory metabolites in (a). Metabolites are coloured according to lipid class. d OPLS-DA of individuals
with (yellow) and without (green) hepatic steatosis as assessed by ultrasound. e Permutation validation of the plot in (d). R2 and Q2 values to the left of
the plot are from random models compared with the values for the true model on the right. f S-plot of discriminatory metabolites in (d). Metabolites
are coloured according to lipid class. CE cholesterol ester, DG diacylglycerol, lyso-PC lyso-phosphatidylcholine, PC phosphatidylcholine, PE
phosphatidylethanolamine, TAG triacylglycerol, SM sphingomyelin. g OPLS-DA scores plot of the TAG profile of individuals with (yellow)
and without (green) hepatic steatosis as assessed by ultrasound. h S-plot of discriminatory TAGs in (g)
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(p = 5*10−30). Examining the variables responsible for this
separation using an S-plot, blood plasma from individuals
with fatty liver were most associated with increases in
TAGs and DAGs, in particular those containing saturated
and monounsaturated FAs with ~ 16–18 carbons in
length, and relative decreases in phosphatidylcholines and
cholesterol esters (Fig. 3f). To demonstrate the predictive
capability of the model we created an OPLS-DA model of
those with only FLI measures (train dataset) to predict the
status of those with both FLI and ultrasound, producing a
receiver operator curve (ROC) with an area under the
curve (AUC) of 0.87 for the test dataset (Additional File 1:
Figure S4a–d).
To further examine the changes in TAGs associated
with hepatic steatosis, we examined the TAG profiles for
those volunteers who had had ultrasound measurements
of fatty liver disease. As part of this analysis for each
person the total intensity of all of the m/z peaks associ-
ated with TAGs was normalised to 100% and each indi-
vidual TAG was represented as a percentage of this
total. Again, OPLS-DA readily separated the two groups
(R2(X) = 43%, R2Y = 11%, Q2 = 9%; Fig. 3g) and the
model passed cross-validation by random permutation
(Additional File 1, Figure S4e) and by CV-ANOVA
(p = 8*10−17). Examining the variables responsible for
this separation using an S-plot, blood plasma from in-
dividuals with fatty liver were most associated with
increases in TAGs 54:2, 48:1, 48:2, 50:1 and 50:2 s
and decreases in TAGs 52:3, 52:4, 56:7, 56:6, 54:4 and
56:8 (Fig. 3h).
Murine studies of de novo lipogenesis
Male ob/ob and C57BL/6 control mice were fed either
on regular chow diet (relatively high in carbohydrate) or
on a high fat diet, and the rate of DNL followed by deu-
teration of palmitate from D2O enrichment in the mouse
body water. Hepatic TAGs were analysed using LC-MS
to assess any effect of diet or genotype on the TAG pro-
file and whether these changes correlated with the rate
of DNL. TAGs in ob/ob mice were compared between
the dietary interventions using PLS-DA (R2X = 90%,
R2Y = 99%, Q2 = 97%), which passed cross-validation by
random permutation and CV-ANOVA (p = 5.85*10−7).
Ob/ob mice fed a regular chow diet had higher concen-
trations of TAGs with shorter, more saturated FA
moieties compared with ob/ob mice on a high fat diet
(Fig. 4a). A more complex pattern was detected for the
wild-type (WT) strain, in part reflecting more modest
DNL with an enrichment of TAGs with 50 and 52 car-
bons, but also reflecting the composition of the high fat
diet (Additional File 1, Figure S5).
The synthesis of palmitate was directly measured by
deuterium incorporation using GC-MS and isotope ratio
mass spectrometry (IR-MS) to normalise for the body
water deuterium enrichment in the ob/ob mice on a
chow diet. The quantity of palmitate synthesis was
assessed by linear regression for its correlation with the
total peak intensity of each TAG detected in the mouse
that relate back to clusters identified in the Fenland
study (Fig. 4b). Fenland cluster 3 produced a positive
correlation (R2 = 0.82, p < 1*10−5) while Fenland TAG
cluster 2 showed no correlation with the rate of DNL in
ob/ob mice (R2 = 0.001, p = 0.91) (Additional File 1,
Figure S6). Fenland TAG cluster 1, however, demon-
strated a negative correlation with rates of DNL, as
assessed by the quantity of de novo synthesised palmi-
tate (R2 = 0.70, p < 5*10−4) (Additional File 1, Figure S6).
To examine these differences in DNL rate, we examined
expression of acetyl CoA carboxylase, fatty acid synthase,
stearoyl-CoA desaturase and elongase 6, confirming that
HFD reduced expression of these transcripts in the re-
spective mouse models (Additional File 1, Figure S7).
Given that leptin has a profound effect on systemic
metabolism, and that the ob/ob mouse does not repre-
sent just a model of hyperphagia but is also hypercorti-
costeronemic, we also studied the effects of a WD (high
in both fat and free sugar) on NAFLD-associated promo-
tion of DNL in WT mice. We fed WT mice either on a
WD or low fat chow (LFC) diet, with the former diet in-
ducing a significant weight gain from week 6 of feeding
(p < 0.05; n = 8; Fig. 5a). Body composition of the mice
measured using TD-NMR after five weeks and 12 weeks
of the dietary intervention showed that while body com-
position stayed constant on the LFC, fat mass significantly
increased on a WD from 21.0 ± 1.4% to 38.9 ± 1.2% (mean
Table 1 Comparison of key anthropometric data for those with
and without hepatic steatosis as measured by ultrasound in the
Fenland cohort. A Student’s t-test was used to compare
parameters between the two groups
Non-steatosis Steatosis
Individuals assessed by ultrasound (n) 663 233
Women (n (%)) 424 (64.0) 110 (47.2)
Age (years) 45 ± 7 48 ± 7***
BMI (kg/m2) 25.5 ± 3.7 30.7 ± 4.8***
Fat mass (kg) 24.2 ± 7.5 33.8 ± 9.5***
Liver score 3.66 ± 0.47 6.06 ± 1.20***
Fasting plasma insulin (pmol/L) 37.9 ± 23.0 68.0 ± 49.4***
Fasting plasma NEFAs (μM) 355 ± 179 369 ± 181
Alcohol consumption (g/d) 9.4 ± 12.3 10.5 ± 14.1
Total carbohydrate consumption 243 ± 106 237 ± 89
Fasting blood glucose (mM) 4.78 ± 0.59 5.12 ± 0.74***
Fasting blood triglyceride (mM) 1.03 ± 0.65 1.70 ± 0.64***
HOMA-IR 0.80 ± 0.49 1.45 ± 1.04***
Fatty Liver Index 31.1 ± 25.4 70.0 ± 24.4***
***p < 0.001
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± standard error; p < 0.0001, n = 8) although no differences
were detected in intraperitoneal glucose tolerance tests at
four and ten weeks of dietary intervention (data not
shown). Histological sections of hepatic slices were stained
using Masson’s trichrome and assessed for the percentage
area of steatotic tissue. WT mice fed a WD demonstrated
significantly increased steatosis compared to those fed
LFC (p < 0.05, n = 8; Fig. 5b).
Palmitate was assessed for the total quantity produced
via DNL using the incorporation of deuterium from
D2O. WT mice fed a WD demonstrated a significantly
increased quantity of DNL-synthesised palmitate com-
pared with WT mice fed LFC (p < 0.0001, n = 8; Fig. 5c).
LC-MS was used to measure the lipidome of liver tissue
to investigate TAG changes induced by the two diets.
Mice fed a WD demonstrated a significant alteration in
TAG profile towards shorter chain, more saturated FA
containing TAGs than LFC fed mice (R2 = 0.731, Q2 =
0.932, p = 8.02 × 10−6 for CV-ANOVA for the associated
PLS-DA plot). Figure 5d displays the most changed
TAGs in liver tissue between the two groups. Although
mice appeared to have a more restricted number of TAGs
within their blood sera than within the hepatic tissue, TAG
profiles were compared using PLS-DA, revealing that mice
fed a WD had an increased proportion of shorter chain
more saturated TAGs than mice fed LFC (R2 = 0.519, Q2 =
0.877, p = 1.07 × 10−4 for CV-ANOVA for the associated
PLS-DA plot). Figure 5d displays the most changed TAGs
in blood sera between the two groups.
Human carbohydrate feeding study in healthy volunteers
Plasma intact lipid profiles were examined following a
high carbohydrate dietary intervention in ten healthy
young adults using DI-MS. There was a significant
change in the blood plasma TAG profile as detected by
OPLS-DA (R2X = 56%, R2Y = 94%, Q2 = 86%), which
passed cross-validation by random permutation and
CV-ANOVA (p = 3.84*10−6). This model demonstrated
an alteration towards shorter chain TAGs with fewer
double bonds after a high carbohydrate meal compared
with fasting, supporting the hypothesis that these TAGs
are increased in concentration by DNL (Fig. 4c).
Fig. 4 a Hepatic TAG changes associated with high fat or regular chow feeding in ob/ob mice. Using partial least squares discriminant analysis
(PLS-DA) to assess the changes in the TAGs within the murine liver demonstrates a shift toward a higher proportion of TAGs with fewer double bonds
and carbon atoms when fed regular chow than when fed a high fat diet. Each point’s area reflects the Variable Importance Parameter score for the
PLS-DA model. b A simple linear model of the summated TAG Fenland cluster 3 signal against calculated de novo synthesised palmitate. Plotting the
total normalised TAG cluster 3 signal against the total palmitate calculated to be synthesised from DNL using deuterium incorporation revealed a
significant positive correlation between the two measurements (R2 = 0.82, p < 1*10−5). c Plasma TAG changes before and after a high carbohydrate
meal. Using PLS-DA to assess the changes in the TAGs within the plasma lipidome demonstrates a shift toward a higher proportion of TAGs with
fewer double bonds and carbon atoms 3.5 h after the high carbohydrate meal compared to before the meal in the fasting state. Each point’s area
reflects the Variable Importance Parameter score for the PLS-DA model. d A simple linear model of the summated TAG Fenland cluster 3 signal against
calculated de novo synthesised palmitate. Plotting the total normalised TAG cluster 3 signal against the proportion of palmitate calculated to be
synthesised from DNL using deuterium incorporation revealed a significant positive correlation between the two measurements (R2 = 0.89, p < 5*10−6)
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The rates of DNL, measured using deuterium incorpor-
ation into palmitate within the TAG lipid fraction, also in-
creased after the meal, peaking at 3.5 h post morning
meal. Across the linear increase in palmitate synthesised
via DNL between 1 and 4 h after baseline measurements,
the fractional synthetic rate of palmitate was 4.41 ± 1.73%
hour−1. To assess the possible correlation between TAG
cluster 3 in the Fenland study and the rate of DNL, the
TAG cluster 3 signal was summated at each time point
and analysed using simple linear modelling against the
DNL rate at that time point (Fig. 4d). This resulted in a
positive correlation between the measured rate of DNL at
that time point and the sum of TAG cluster 3 peaks
(R2 = 0.89, p < 5*10−6). Examining the second cluster of
TAGs, containing longer, more unsaturated fatty acids
and akin to clusters 1 and 2 in the Fenland cohort, there
was a significant negative correlation with palmitate syn-
thesised via DNL (Additional File 1, Figure S8).
The association of other risk factors with the TAG cluster
containing saturated FAs (Fenland)
To investigate further the TAGs associated with DNL, we
performed a combination of linear regression and logistic
regression of these factors with a range of other explana-
tory variables measured in the Fenland study (Additional
File 1: Figure S9). The absolute level of each of the TAG
species was increased with increasing hepatic steatosis.
The series of multivariable adjusted analyses showed that
lifestyle (diet and physical activity) and genetic factors
(single nucleotide polymorphisms (SNP) previously
associated with hepatic steatosis: SNPs LYPLAL1
(rs12137855); GCKR (rs780094); PPP1R3B (rs4240624);
NCAN (rs2228603); PNPLA3 (rs738409); SREBP-1f
(rs11868035)) had little impact on the associations
(Additional File 1: Table S1). However, PPP1R3B
(rs4240624)) was strongly associated with all the TAG
markers and was unaffected by adjustment for age, sex or
BMI (p < 0.02 for TAGs 46:1, 46:2, 48:1, 48:2 and 50:1)
(Additional File 1: Table S2). HOMA-IR and visceral fat/
waist circumference explained a high proportion of the as-
sociation between individual TAGs and hepatic steatosis;
the associations for TAG(46:1) and TAG(48:2) were most
influenced by adjustment for HOMA-IR and TAG(48:1)
and TAG(50:1) were most influenced by waist/visceral adi-
posity. However, when adjusting for these factors, a posi-
tive association remained between TAG (50:1), the most
intense TAG species, and liver fat (p < 0.05), indicating this
association remained after correcting for all covariates.
Analysis of TAGs with FLI (Fenland)
Performing linear regression, TAG(48:1), TAG(48:2) and
TAG(50:1) were associated with FLI after adjustment for
all covariates (Additional File 1: Tables S3–6). In addition
TAG(46:1) was associated with FLI adjusted for BMI but
not after adjusting for waist or visceral adipose tissue
volume. Thus, across both analyses the cluster of TAGs
associated with shorter, more saturated FAs containing
myristate, palmitate and stearate were associated with
Fig. 5 a Body mass of mice over the duration of the dietary intervention. WT mice fed low fat chow (LFC) were significantly lighter than those
fed a Western diet (WD) from 6 weeks onward (p < 0.05; n = 8). b Histological assessment of hepatic steatosis. Masson’s trichrome stained sections
were used for histological analysis and lipid content assessed as the average percentage of the hepatic tissue that appeared as unstained lipid
droplets. Mice fed a LFC diet had significantly lower lipid content than mice fed WD. Mean ± SEM analysed by two-way ANOVA and Tukey’s
multiple comparison test. c Overall quantity of DNL synthesised palmitate. Mice fed a WD demonstrate significantly increased production of
palmitate compared to those fed LFC. Mean ± SEM analysed by two-way ANOVA and Tukey’s multiple comparison test. d LC-MS analysis of intact
TAGs within the liver and blood plasma. TAGs that were significantly increased in each group were plotted by number of carbon atoms against
number of double bonds within the FA moieties, when compared pairwise using PLS-DA with a VIP > 1 being taken as significant
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increased hepatic steatosis as measured by ultrasound
and FLI. For TAG (48:1), TAG(48:2) and TAG (50:1),
these associations remained after correction for all co-
variates including sex, age, genetic factors and lifestyle
factors.
Dietary variables which have been associated with
increased lipogenesis and liver fat include a WD rich
in fat, particularly saturated fat, refined sugars and
fructose (particularly in the context of beverages)
[20, 23]. We investigated whether dietary variables
were associated with TAGs to determine if dietary
variables are mediators in the association between
TAG markers and steatosis. The only dietary factors
which appeared to modify the TAG markers were sat-
urated fat and free sugar (WHO definition, analogous
to non-milk extrinsic sugars-NMES). The association
between saturated fat intake and these TAGs was
independent of HOMA-IR, BMI and visceral fat
(Additional File 1: Table S5). The association between
proportion of free sugar in the habitual diet and most
TAGs modelled was partly mediated by adiposity and
insulin sensitivity (Additional File 1: Table S6).
Specific TAGs are markers of liver fat in biopsy confirmed
non-alcoholic steatohepatitis (NASH)
Finally, we confirmed the importance of the TAGs
previously described in steatosis in the sera of a cohort
of biopsy proven NASH patients (Table 2). When using
the ‘steatosis’ component of the NAFLD activity score
(NAS) to discriminate the amount of fat accumulation
in the liver (0–1 vs 2–3), the lipid profiles of these pa-
tients showed TAG(50:0), TAG(48:1), TAG(50:1) and
TAG(48:0) to be increased in the patients with higher fat
accumulation (p = 0.043, 0.039, 0.034 and 0.0056, re-
spectively; Student’s t-test) (Fig. 6a). These TAG species
were found to be highly correlated across this patient
group, in part confirming previous clusterings detected
in the Fenland and NSHD cohorts (Fig. 6b).
Discussion
In this series of inter-related studies, we profiled the
lipid content of > 3000 individuals from two large-scale
cohort studies, two murine dietary intervention studies
and a physiological study of DNL in order to investigate
why a sub-set of TAGs is associated with the develop-
ment of T2DM, possibly through the prior development
of hepatic steatosis [10–14]. Of all the lipid species
measured in our lipidomic assay, only TAGs showed evi-
dence of sub-structure. Bayesian hierarchical cluster ana-
lysis revealed that there were three distinct clusters of
TAGs that were found across all three human studies
and also found to be repeated broadly in both WT and
obese mice. We identified that one of these clusters,
representing ~ 34% of the total TAG signal in the mass
spectra, was selectively associated with hepatic steatosis,
both as measured by ultrasound and FLI. To investigate
this cluster of TAGs further, we performed three dietary/
physiological interventions in mice and healthy humans
to see whether increased DNL in turn could contribute
to increases in these TAGs which contain shorter and
more saturated FAs (FAs with 16–18 carbons which are
saturated or monounsaturated). In the two experiments
where DNL was also directly measured using GC-MS to
detect the incorporation of deuterium into saturated FAs
from D2O in the body, these TAGs were increased in
concentration in high correlation with DNL. Interest-
ingly, the contribution of TAGs containing longer, more
unsaturated fatty acids were negatively correlated with
DNL. Furthermore, these TAGs, with fatty acids contain-
ing 16-18 carbons which are saturated or monounsatu-
rated, were found to be increased in blood plasma from
patients with biopsy confirmed hepatic steatosis.
We then investigated factors contributing to the
plasma concentrations of these TAGs. We found that
TAGs with 46–50 carbons with one or two double
bonds were associated with hepatic steatosis even after
adjusting for sex, age, genetic factors (SNPs known to be
associated with fatty liver disease) and lifestyle factors
Table 2 Characteristics of cohort of biopsy-proven NASH patients
Steatosis 0–1 Steatosis 2–3 p (T-test)
n 40 36 /
M/F 22/18 24/12 NS (Chi-Squared)
Age (years) 58.5 ± 1.7 53.6 ± 1.9 NS (0.06)
BMI (kg/m2) 31.6 ± 0.6 32.6 ± 0.9 NS
Metabolic assessment
Glucose (mmol/L) 6.2 ± 0.3 7.0 ± 0.4 NS (0.1)
Insulin (pmol/L) 109.6 ± 11.0 130.7 ± 12.6 NS
HOMA2-IR 2.1 ± 0.2 2.5 ± 0.2 NS
TAGs (mmol/L) 1.8 ± 0.2 1.9 ± 0.3 NS
Total cholesterol (mmol/L) 4.3 ± 0.2 4.3 ± 0.1 NS
LDL cholesterol (mmol/L) 2.6 ± 0.2 2.6 ± 0.1 NS
HDL cholesterol (mmol/L) 1.0 ± 0.1 1.0 ± 0.03 NS
Liver function tests
AST (U/L) 41.5 ± 3.8 46.7 ± 3.9 NS
ALT (U/L) 53.02 ± 3.9 72.9 ± 6.3 < 0.01*
ALP (U/L) 118.4 ± 9.5 104.1 ± 6.7 NS
Histology
NASH activity score 2.8 ± 0.2 4.8 ± 0.2 < 0.01*
- Steatosis 0.8 ± 0.02 2.3 ± 0.1 < 0.01*
- Ballooning 0.7 ± 0.1 1.0 ± 0.1 0.03*
- Inflammation 1.4 ± 0.1 1.5 ± 0.1 NS
Fibrosis 1.5 ± 0.2 1.8 ± 0.2 NS
* p < 0.05
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(physical activity, dietary factors and alcohol). For TAGs
46:1 and 48:2, these lipids were associated with IR and
hepatic steatosis, while TAGs 48:1 and 50:1 were associ-
ated with visceral fat and hepatic steatosis. Dietary fac-
tors, saturated fat and sugar intake were strongly
associated with these TAGs, although this was strongest
for relative proportion rather than total amount per se.
Luukkonen et al. [24] also have reported increases in
these TAGs in liver biopsies from individuals with high
HOMA-IR in patients with NAFLD. One concern with
using FLI as a proxy for hepatic steatosis is that this
index uses total serum TAG as one of the measures to
calculate the index. However, we used in addition both
ultrasound and liver biopsy as independent approaches
for measuring hepatic steatosis, giving comparable re-
sults to using FLI. This may suggest that the particular
TAGs identified as being associated with hepatic steato-
sis may be more sensitive measures compared with total
TAG content used in the FLI, especially as TAGs con-
taining longer, more unsaturated fatty acids are nega-
tively correlated with hepatic steatosis.
While DNL has classically been thought to play a rela-
tively minor role in total saturated FA content of the
mammalian body [8], Lambert et al. [16] identified a
number of limitations to this generalisation. First, many
of the early studies measuring DNL are in the fasting
state, where DNL is suppressed [25]. Second, DNL rates
are lower in healthy, lean individuals compared with
obese and IR individuals [17, 26]. Moreover, Lambert et
al. questioned whether the period of observation of
labelling with deuterium from D2O was too short in
previous studies as the appearance of lipid can be de-
layed significantly in intrahepatic stores. Indeed, they ex-
perimentally demonstrated that in individuals with high
liver fat the contribution of DNL to VLDL TAG content
doubled to ~ 23% compared with individuals with low
liver fat. Increased DNL is associated with increased size
of VLDL particles, with Fabbrini et al. [27] making the
intriguing observation that while apoB100 production is
proportional to VLDL secretion and DNL production of
FAs in the liver in individuals with normal hepatic fat
content, apoB100 production does not keep pace with
TAG VLDL secretion in fatty liver disease, first leading
to increased VLDL particle size and then increased
hepatic TAG deposition as export of de novo FAs is
impaired.
The analyses of TAGs containing 46–50 carbons with
one or two double bonds identified two TAGs (48:1 and
50:1) associated with both visceral fat and liver fat and
two others (46:1 and 48:2) associated with whole-body
IR and liver fat. Whole-body IR has been identified as
one of the major influences on hepatic steatosis [28].
Furthermore, it can be difficult to distinguish the contri-
bution of DNL production of FAs in the liver and in
adipose tissue in terms of the total blood plasma con-
tent. However, in a previous study of lipodystrophy we
demonstrated that raised blood plasma concentrations
of TAGs with 46–50 carbons with one or two double
bonds were enriched in the VLDL fraction, strongly sug-
gesting their hepatic origin [19]. In addition, Fabbrini et
al. [29] examining obese individuals matched for either
visceral adipose tissue (VAT) or intrahepatic TAG
Fig. 6 a Boxplots of the relative intensities of triacylglycerols TAG(50:1) and TAG(48:1) in blood plasma of patients with biopsy confirmed NASH
separated according to ‘steatosis’ component of the NAFLD Activity score. No steatosis: score of 0 or 1, steatosis: score of 2 or 3. b Heat map of
the correlation of the most discriminatory lipids between those with a low steatosis score (0 or 1) or high steatosis score (2 or 3). TG
triacylglycerol, PC phosphatidylcholine, PI phosphatidylinositol, DG diacylglycerol
Sanders et al. Genome Biology  (2018) 19:79 Page 10 of 15
(IHTG) content provided compelling evidence that
IHTG was a better predictor of hepatic, adipose and
skeletal muscle insulin sensitivity and VLDL-TAG secre-
tion than VAT.
The recent increase in prevalence of NAFLD [30],
even in children [31], raises the question as to whether
environmental factors and, in particular, diet may play
an important role. In most western countries the
nutritional guidance for the past 30–40 years has been
to reduce total fat and cholesterol content in our diets.
However, that has been at the same time as an increase
in carbohydrate consumption, particularly in the form of
sugary drinks and fruit juices which can rapidly raise the
concentration of glucose and fructose in the blood,
stimulating DNL [32]. Indeed, recent findings from the
EPIC InterAct study of eight countries across Europe re-
ported that the saturated FAs myristate, palmitate and
stearate were associated with increased incidence of
T2DM [15]. In that study, these saturated fatty acids
were correlated with the consumption of sugary drinks,
alcohol (another DNL substrate) and potatoes, suggest-
ing that such carbohydrate rich foods are likely to stimu-
late DNL which in turn may contribute to increased
circulating concentrations of these fatty acids [15]. How-
ever, it should be noted that in the Fenland and NSHD
cohorts, the TAGs we detected containing shorter, more
saturated fatty acids could also arise from food sub-
stances high in saturated fatty acids as well as from car-
bohydrates via DNL.
There has been much interest in the field of metabolo-
mics in the generation of predictive markers of T2DM
and its associated metabolic diseases [33, 34]. One of the
most reproducible set of prospective biomarkers of IR and
T2DM are TAGs with shorter, more saturated FAs, first
reported in the Framingham cohort [10] and since
reproduced in a number of large cohort studies as well as
the investigation of rarer patient groups of T2DM [11, 12,
14, 19, 35]. In a cohort of 679 well-characterised individ-
uals, where fatty liver was assessed either by magnetic
resonance imaging or liver biopsy, a ‘lipid triplet’ bio-
marker based on TAG(16:0/18:0/18:1), PC(18:1/22:6) and
PC(O-24:1/20:4) had a sensitivity of 69.1% and specificity
of 73.8%, demonstrating the potential of TAGs containing
saturated fatty acids as diagnostic markers [36].
In addition to investigating the association between
different TAG species and fatty liver disease we also ex-
amined whether SNPs known to be associated with fatty
liver disease also were associated with changes in the
concentration of TAGs that were most increased in fatty
disease. The SNP rs4240624 in protein phosphatase 1,
regulatory subunit 3B (PPP1RB) was strongly associated
with the blood plasma relative concentrations of TAGs
46:1, 46:2, 48:1, 48:2 and 50:1. PPP1RB encodes the
catalytic subunit of the serine/threonine phosphatase,
protein phosphatase-1 and in turn the phosphatase regu-
lates glycogen synthesis in liver and skeletal muscle. Var-
iants in the gene, including those found at rs4240624,
have been associated with susceptibility to fatty liver
disease [37, 38]. However, this is the first time that gen-
etic variants in this gene have been directly associated
with changes in blood lipidomics. A reduced capacity to
store glucose as glycogen would increase the relative
proportion of glucose being converted to fatty acids as
part of DNL, providing a plausible mechanistic explan-
ation for the association between PPP1RB and TAGs
containing saturated and monounsaturated fatty acids
derived from DNL.
An important remaining question is whether the TAG
species identified as associated with hepatic steatosis are
causal for or a consequence of the development of
NAFLD. TAGs are thought to be relatively unreactive
compared with other lipid classes and it is unlikely that
TAGs themselves are responsible for the development of
IR and subsequent T2DM [39]. However, TAGs are syn-
thesised via DAGs and these lipids have been shown to
interfere with insulin signalling by activating protein kinase
CƐ (PKCƐ) which leads to reduced insulin-stimulated
insulin receptor substrate 2 (IRS-2) tyrosine phosphoryl-
ation [40, 41]. Indeed, increasing TAG synthesis by
overexpressing diacylglycerol acyltransferase 2 (DGAT2)
specifically in the liver of mice has been shown to increase
the total liver content of DAGs as well as TAGs, increase
the activity of PKC and reduce the phosphorylation of
IRS-2 [42]. In addition, palmitate and DAGs from DNL
have been specifically associated with increased ER stress.
Obesity is responsible for suppression of insulin signalling
by hyperactivation of c-jun N-terminal kinase (JNK)
through increased ER stress [43, 44]. Saturated fats, in par-
ticular palmitate and stearate, have been shown to be po-
tent inducers of ER stress and apoptosis in hepatic cells
[45]. It is not clear whether palmitate and stearate act dir-
ectly to modulate the cellular membranes or induce the
synthesis of other lipotoxic intermediates. Wei et al.
demonstrated palmitate induced ER-stress in the absence
of ceramide accumulation [45], while Chan et al. linked
fructose-induced ER stress in the mouse liver to increased
DNL and accumulation of hepatic DAGs [46].
Conclusions
We have identified a cluster of TAG species which to-
gether are associated with hepatic steatosis. These TAGs
are increased in concentration during raised DNL, as
well as being associated with the proportion of free
sugar in habitual diet and dietary saturated fat, and may
provide a more sensitive marker for the metabolic
consequences of fatty liver disease than measurements
of total blood TAG concentrations.
Sanders et al. Genome Biology  (2018) 19:79 Page 11 of 15
Methods
Human cohort studies
Fenland: Plasma samples from 1507 individuals from a
sub-set of the Fenland cohort (http://www.mrc-epid.ca-
m.ac.uk/Research/Studies/Fenland/; Table 3) were stored
at − 80 °C before analysis. The liver fat content of indi-
viduals was assessed by ultrasound for 901 participants.
Analyses were compared with FLI, based on BMI, waist
circumference, total TAGs and plasma levels of GGT
[21]. Further details are given in the supplementary
methods section.
Medical Research Council NSHD cohort: To replicate
the TAG identification in the Fenland cohort, plasma
samples from 1701 individuals were analysed from the
NSHD cohort [47]. Summary statistics for this cohort
are presented in Table 3. Fatty liver status was not
assessed in this cohort.
Murine dietary intervention studies
All procedures involving mice were performed by a li-
cence holder in accordance with the UK Home Office
Animals (Scientific Procedures) Act 1986, and the
University of Cambridge Animal Welfare and Ethical
Review Committee.
In the first study, six-week-old male ob/ob mice and
C57BL/6 controls were fed on regular chow diet (energy
composition: 11.5% fat, 26.9% protein, 61.6% carbohy-
drate; Rat & Mouse No. I Maintenance; Special Diet Ser-
vices, UK) or a high-fat diet previously described [48]
(energy composition: 55% fat, 29% protein, and 16%
carbohydrate; diet code: 829197; Special Diet Services,
UK) (n = 7 per diet and genotype). The FA composition
of the high fat diet was 25% polyunsaturated FAs, 48%
monounsaturated FAs and 27% saturated FAs.
Temperature was maintained at 20 ± 4 °C with a 12 h
light/dark cycle. All mice drank water enriched with
deuterium adjusted for each group depending on diet
and average mouse weight to gain roughly 1% enrich-
ment in body water for analysis of DNL. This was
maintained for 14 days to achieve steady-state of enrich-
ment. Animals were killed by CO2 asphyxiation,
exsanguinated and dissected to collect hepatic tissue,
which was flash frozen in liquid nitrogen and stored.
In the second study, five-week-old male C57bBl/6
mice (n = 8) were fed either a LFC diet (TD08485, Tek-
lad Custom Research Diets, Envigo, Huntingdon, UK) or
WD (TD88137) for 12 weeks. At the end of the fourth
and tenth week each mouse underwent an intraperito-
neal glucose tolerance test (IP GTT), and during the
fifth and 12th week of the dietary intervention, the body
composition of the mice was analysed by time domain
nuclear magnetic resonance (TD-NMR) using a Bruker
LF90 Minispec (Bruker Corp., Coventry, UK). After the
second IP GTT mice were provided with D2O-enriched
drinking water adjusted for each group depending on
diet and average mouse weight to gain roughly 1% en-
richment in the mice’s body water for the analysis of
DNL. This was maintained for the final two weeks of the
study to allow sufficient steady-state enrichment of the
body water. Twelve weeks after the start of the dietary
intervention mice were killed by cervical dislocation.
The animals were then exsanguinated and dissected to
collect hepatic tissue, which was flash frozen in liquid
nitrogen and stored at − 80 °C until required for analysis.
Hepatic samples for each mouse were also fixed in
formalin for histological analysis. Serum was isolated
from the collected blood by centrifugation at 3000 g for
10 min and stored at − 80 °C until analysis.
Carbohydrate overfeeding in healthy human adults
This study was approved by Cambridge South Research
Ethics Service Committee (Ref. no. 14/EE/0054). After
an overnight fast, ten healthy volunteers (BMI = 22.2 ±
1.2 kg/m2, fasting blood triglyceride = 1.0 ± 0.5 mM,
fasting blood glucose = 4.9 ± 0.4 mM) were provided with
breakfast comprising 45% of their basal metabolic rate
(BMR) [49] (61.5% carbohydrate [CHO], 21.2% fat and
17.3% protein by energy composition). Deuterium-labelled
water (3 g/kg body water) was provided in two portions of
equal sizes. After 3.5 h they were provided with a meal,
which contained 47.5% of their BMR (65.4% CHO, 22.6%
fat and 12.0% protein). The evening meal contained 47.5%
BMR (61.1% CHO, 23.9% fat and 15.0% protein). The
following morning a basal blood sample was taken for fasted
state isotopic compositions of lipids and lipid profiling. A
Table 3 Comparison of the two cohorts used in the
manuscript. Fenland and the National Survey of Health and
Development (NSHD) are UK prospective cohort studies.
Fenland (http://www.mrc-epid.cam.ac.uk/research/studies/
fenland/) investigates the interaction between environmental
and genetic factors in determining obesity, type 2 diabetes and
related metabolic disorders. NSHD (http://www.nshd.mrc.ac.uk)
is a British birth cohort study investigating the social and
biological factors that affect lifelong health, ageing and the
development of chronic disease risk
Analysis of the sub-
cohort of Fenland
NSHD
Individuals (n) 1507 1701
Hepatic steatosis assessed
by ultrasound (n)
901 Not determined
Hepatic steatosis assessed
by Fatty Liver Index (n)
1507 Not determined
Women (%) 55.8 52.1
Age (years) 45 ± 7 62 ± 2
Fasting blood
triglyceride (mM)
1.22 ± 0.84 1.08 ± 0.10
BMI (kg/m2) 27.0 ± 4.8 27.6 ± 4.5
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breakfast, identical to the previous morning, was provided,
and blood samples (12 mL per sample) were taken every
hour for 4 h. Lunch contained energy equivalent to 110% of
BMR (69.7% CHO, 22.1% fat and 8.2% protein). Hourly
blood samples (12 mL) were taken for a further 5 h.
Mass spectrometry
DI-MS of blood plasma in the cohorts and feeding
studies The method has been described previously [19]
and is given in detail in the supplementary information.
Lipid species from 15 μL of blood plasma were analysed
on an Advion Triversa Nanomate interfaced with an
Exactive MS (Thermo Scientific, Hemel Hempstead,
UK). Features of interest were subsequently confirmed
using fragmentation experiments on a Thermo Velos
Orbitrap Elite MS in conjunction with chromatography
using the ultra-high performance liquid chromatography
(UHPLC) U3000 unit.
LC-MS of mouse liver tissue LC-MS experiments were
carried out using Thermo Scientific U3000 Autosampler
coupled to a Thermo Scientific Elite™ Iontrap-Orbitrap
Hybrid MS (Thermo Scientific, Hemel Hempstead, Hert-
fordshire, UK). A total of 5 μL of extracted tissue was
injected onto an Acuity C18 BEH column (Waters™ T3
50 × 2.1 mm, 1.7 μm) maintained at 55 °C. Further de-
tails are given in the supplementary data.
GC-MS of mouse liver tissue to determine relative
enrichment of TAG FAs following DNL Lipids were
pre-fractionated using solid phase extraction (SPE) with
50 mg sodium sulphate/NH2 100 mg cartridges (Agilent
Technologies, Santa Clara, CA, USA). The fractional
synthetic rate of TAG FAs was determined using the in-
corporation of deuterium into TAG FA methyl esters
(FAMEs) from deuterium-enriched water as previously
described [17, 50].
Statistical analysis The Fenland cohort: We tested asso-
ciations of TAG(46:1); TAG(46:2); TAG(48:1); TAG(48:2)
and TAG(50:1) with hepatic steatosis as assessed by ultra-
sound and FLI using ordinal logistic regression and esti-
mating odds ratios. All analyses were adjusted for analysis
batch and total TAGs. The analyses were further adjusted
for potential confounders and mediators that could
influence TAGs and hepatic steatosis including intrinsic
characteristics (age, sex, genotype [SNPs LYPLAL1
(rs12137855); GCKR (rs780094); PPP1R3B (rs4240624);
NCAN (rs2228603); PNPLA3 (rs738409); SREBP-1f
(rs11868035)]) and lifestyle characteristics (dietary variables,
physical activity, smoking, alcohol intake). We further
evaluated whether the associations of TAGs with hepatic
steatosis were explained by metabolic perturbations (insulin
sensitivity, obesity and central adiposity). All cohort
analyses were conducted using Stata version 14 (StataCorp
LP, TX, USA). Further details are provided in the supple-
mentary methods.
Multivariate analyses of the cohorts, mouse study and
human carbohydrate overfeeding study: For multivariate
analysis, all data were mean centred and Pareto scaled be-
fore subsequent analysis. Clustering tendencies of data
were visualised using the package ‘pheatmap’, and
Hopkin’s statistics, H, were calculated using the package
‘factoextra’ within R. The null hypothesis that the data has
no substructure is rejected at the 95% confidence level if
H > 0.6799 [51]. For further exploration of clustering
within the whole lipidomic datasets agglomerative hier-
archical clustering (from the ‘stats’ package) with‘Com-
plete’ (farthest neighbour) linkage and Euclidean distance
[52], the k-means algorithm (from the ‘stats’ package) was
run with a Euclidean distance measure, and the
self-organising maps method, from the ‘SOMbrero’ pack-
age in R [53] all within R. To further explore the cluster-
ing within the TAG species, Bayesian hierarchical cluster
analysis as described by Heller and Ghahramani [54] was
performed within R to compare the profiles of TAG spe-
cies across the Fenland and NSHD datasets. PCA and
OPLS-DA was used within Simca (version 13, Umetrics,
Umea, Sweden) to compare lipid profiles. Model validity
was assessed by R2, Q2, the random permutation test and
CV-ANOVA within the Simca package.
Additional file
Additional file 1: contains all the additional supplementary data in the
form of a Word document. (DOCX 1130 kb)
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